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Abstract
Enhanced matrix metalloproteinases (MMPs) activity is implicated in the process of atherosclerotic plaque instability. We
hypothesized that doxycycline, a broad MMPs inhibitor, was as effective as simvastatin in reducing the incidence of plaque
disruption. Thirty rabbits underwent aortic balloon injury and were fed a high-fat diet for 20 weeks. At the end of week 8,
the rabbits were divided into three groups for 12-week treatment: a doxycycline-treated group that received oral
doxycycline at a dose of 10 mg/kg/d, a simvastatin-treated group that received oral simvastatin at a dose of 5 mg/kg/d, and
a control group that received no treatment. At the end of week 20, pharmacological triggering was performed to induce
plaque rupture. Biochemical, ultrasonographic, pathologic, immunohistochemical and mRNA expression studies were
performed. The results showed that oral administration of doxycycline resulted in a significant increase in the thickness of
the fibrous cap of the aortic plaque whereas there was a substantial reduction of MMPs expression, local and systemic
inflammation, and aortic plaque vulnerability. The incidence of plaque rupture with either treatment (0% for both) was
significantly lower than that for controls (56.0%, P,0.05). There was no significant difference between doxycycline-treated
group and simvastatin-treated group in any serological, ultrasonographic, pathologic, immunohistochemical and mRNA
expression measurement except for the serum lipid levels that were higher with doxycycline than with simvastatin
treatment. In conclusion, doxycycline at a common antimicrobial dose stabilizes atherosclerotic lesions via inhibiting matrix
metalloproteinases and attenuating inflammation in a rabbit model of vulnerable plaque. These effects were similar to a
large dose of simvastatin and independent of serum lipid levels.
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Introduction
Atherosclerosis is a complex inflammatory and proliferative
process and plaques vulnerable to rupture, the major cause of
acute coronary syndrome, are characterized by an atrophic fibrous
cap, a lipid-rich necrotic core, accumulation of inflammatory cells
such as monocytes/macrophages, and imbalance between extra-
cellular matrix synthesis and degradation [1,2]. Therefore, the
major determinants of plaque vulnerability are progressive lipid
accumulation (core formation) and fibrous cap weakening due to
ongoing inflammation with collagen degradation (macrophages-
related) and impaired healing and repair [vascular smooth muscle
cells (VSMCs)-related].
A wealth of evidence has pointed to matrix metalloproteinases
(MMPs) as a major molecular mediator of plaque vulnerability
[3,4]. MMPs are a group of more than 20 zinc-containing
endopeptidases that are secreted or expressed at the cell surface of
all main vascular cell types. Members of the MMPs family include
collagenases (MMP-1, MMP-8 and MMP-13), gelatinases (MMP-
2 and MMP-9), stromelysins (MMP-3, MMP-10 and MMP-11),
matrilysins (MMP-7) and membrane-type MMPs, and each of
these MMPs can process at least one type of extracellular matrix
(ECM). MMPs have overlapping specificities, but specific MMPs
may have different and even contradicting roles in the natural
history of atherosclerosis. Pathological findings have implicated
MMPs in all stages of atherosclerosis, from lesion formation to
plaque progression. A role of MMPs in atherogenesis may be
inferred by the detection of MMP-1, MMP-2, MMP-3, MMP-9
and MMP-12 in atherosclerotic lesions [3,4]. In the early stage of
atherosclerosis, MMPs may facilitate migration of VSMCs and
monocytes/macrophages, and thus enhance plaque formation. In
the late stage of atherosclerosis, accumulated MMPs may degrade
the fibrous cap and lead to plaque disruption and atherothrom-
bosis, causing acute coronary syndromes. Thus, MMPs might offer
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stabilization. One approach to the inhibition of MMPs is to use
pharmacological inhibitors. Although statins are effective in
inhibiting MMPs expression in atherosclerotic lesions, it may
cause side effects such as liver dysfunction and myopathy in some
patients. Recent studies found that doxycycline, a well-known
antibiotic drug, may exert powerful inhibitory effects on MMPs
activity. However, in different experimental and clinical studies,
doxycycline treatment exhibited diverse or even opposite impacts
on plaque stability and patient outcome, making such a therapy
inconclusive [5,6,7]. In the present study, we hypothesized that
doxycycline was as effective as simvastatin in reducing the
incidence of plaque disruption via inhibiting MMPs activity and
attenuating local inflammation. A series of experiments in vivo and
in vitro were designed and performed to test this hypothesis.
Materials and Methods
Ethics Statement
The experiments complied with the Animal Management Rule
of the Chinese Ministry of Health (documentation 55, 2001), and
the experimental protocol was approved by the Animal Care
Committee of Shandong University.
Animal protocol
A total of 30 male New Zealand White rabbits weighing 2–3 kg
were housed at the Animal Care Center of Shandong University
Qilu Hospital. All rabbits underwent balloon-induced endothelial
injury of the abdominal aorta and received a high-fat diet (1%
cholesterol, Shandong Experimental Animal Center, Jinan, China)
feeding for 20 weeks. Balloon-induced aortic wall injury was
performed with a 4-F balloon catheter (balloon size of 3.5 mm in
diameter and 15 mm in length) introduced through the right
femoral artery to the thoracic aorta after anesthetization. The
balloon was inflated with saline to increase the pressure to 8 atm
and the catheter was retracted down to the iliofemoral artery. This
process was repeated three times in each rabbit to ensure
denudation of the endothelium of the abdominal aorta. From
the end of week 8 to the end of week 20, rabbits were randomly
divided into three groups (n=10 each): doxycycline-treated group
that received doxycycline (Chemical material plant, Jiangsu,
China) at an oral dose of 10 mg/kg/d [8], simvastatin-treated
group that received simvastatin (Merck & Co. Inc, Hangzhou,
China) at an oral dose of 5 mg/kg/d, and control group that
received no treatment. These drugs were supplemented in water
and administered by oral gavage. At the end of week 20, all rabbits
underwent pharmacological triggering as described previously
[9,10]. In brief, 0.15 mg/kg of Chinese Russell’s viper venom was
injected intraperitoneally, followed 30 min later by an intravenous
injection of 0.02 mg/kg histamine (Sigma, St. Louis, MO, USA).
High-frequency ultrasonography and intravascular ultrasound
imaging were performed in all rabbits before pharmacological
triggering to examine the morphological changes of the aortic
plaques. Rabbits were euthanized 24 hr after pharmacological
triggering by intravenous injection of an overdose of pentobarbital.
Measurement of doxycycline plasma concentration
Blood samples were collected from all rabbits of doxycycline-
treated group, and the plasma concentration of doxycycline was
monitored by high-performance liquid chromatography (HPLC)
[11] by use of a Waters 515 HPLC instrument at day 1 and week
1, 4, 8 and 12 after doxycycline administration. Separation was
performed on a Waters analytical column (4.66250 mm, 5 mm),
with the mobile phase consisting of acetonitrile and water with
gradient elution at a flow rate of 0.8 ml/min and a column
temperature of 30uC. The UV wavelength used for detection was
347 nm and the analysis time 6.195 min.
The standard curve of plasma concentration of doxycycline was
identified on the HPLC chromatogram and individual plasma
concentrations of doxycycline were calculated from the regression
equation obtained from 7 standard concentrations (0.1, 0.25, 0.5,
1.0, 2.0, 4.0, and 8.0 mg/ml).
Biochemical studies
In all rabbits, blood samples were collected at the beginning of
the experiment and before pharmacological triggering. Serum
levels of total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C) and low-density lipoprotein
cholesterol (LDL-C) were measured by enzymatic assays. Serum
levels of high sensitive C-reactive protein (hs-CRP), monocyte
chemoattractant protein-1 (MCP-1), interleukin (IL)-8, IL-18,
MMP-1 and P-selectin were assayed by use of ELISA kits (R&D
Systems, Chicago, IL, USA).
Ultrasonographic Study
High-frequency ultrasonography. A high-frequency du-
plex ultrasonographic system (HP SONOS 5500, Andover,
Massachusetts, USA) connected with a 7.5-MHz transducer were
applied to detect the aortic plaques before pharmacological
triggering. The aortic diameter at end-diastole (Dd) and the
maximal intima-media thickness (IMT) were measured and the
aortic peak velocity (Vp), mean velocity (Vm) and velocity-time
integral (VTI) were recorded.
Integrated backscatter analysis. The acoustic densitome-
try technique was applied to analyze the ultrasonic integrated
backscatters from the aortic wall and plaques. The ultrasonic
intensity (AII) of the aortic intima and adventitia in normal
segments and aortic plaques were recorded, and the corrected AII
Table 1. Primers for RT-PCR.
molecules loci primer sequence
GAPDH NM_001082253 S: GAGCTGAACGGGAAACTCAC
A: GGTCTGGGATGGAAACTGTG
p-selectin NM_001082755 S: CTGACAATGAGCCTAACAACAAG
A: CTATAGCAGAGTGCTCGCTTTC
MCP-1 NM_001082294 S: CAGCCAGATGCCGTGAA
A: TTGGGTTGTGGAATAAGAGGT
MMP-1 NM_001082793 S: GAGGAGGAGACGGAGGTGAT
A: GGGAACGCTGGCAGTAGAG
MMP-2 NM_001082209 S: GTCTGAAGAGCGTGAAGGTTGG
A: GTTGACGGGATTGGAGGGGAAG
MMP-3 NM_001082280 S: CGCTTTGCTCAGCCTATCCAC
A: CCAACATCAGGAACGCCACA
MMP-9 NM_001082203 S: CGGAGCACGGAGACGGGTAT
A: GATGAAGGGGAAGTGGCAGG
MMP-12 NM_001082771 S: GGCACAAACTTGTTCCTTGTTG
A: TGGGTTGATGCTGCTCTGG
GAPDH: glyceraldehydes 3-phosphate dehydrogenase; MCP-1: monocyte
chemoattractant protein-1; MMP-1: matrix metalloproteinase 1; MMP-2: matrix
metalloproteinase 2; MMP-3: matrix metalloproteinase 3; MMP-9: matrix
metalloproteinase 9; MMP-12: matrix metalloproteinase 12.
doi:10.1371/journal.pone.0039695.t001
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the adventitia in both normal segments and plaques.
Intravascular ultrasound (IVUS) imaging. IVUS imaging
was performed before pharmacological triggering using a 3.2 F
catheter that contains a single rotating element transducer of
40 MHz connected to an IVUS system (Galaxy, Boston Scientific
Corp., Fremont, CA, USA). The catheter was withdrawn from the
aortic arch to the abdominal aorta with a motorized pullback
device at a constant speed of 0.5 mm/s. The external elastic
membrane area (EEMA) and lumen area (LA) were measured to
calculate the plaque area (PA) as: PA=EEMA-LA, and plaque
burden was then derived using the formula: PB%=PA/
EEMA6100%.
Histopathology and immunohistochemistry
The abdominal aorta was examined to observe the incidence of
plaque rupture and thrombosis. Tissue samples 2 cm long were
taken from the abdominal aorta and fixed in 4% formaldehyde.
Some segments were embedded in paraffin and cut into 5-mm-
thick sections for staining with hematoxylin and eosin (H&E) and
Masson trichrome, whereas other sections were stained with sirius
red and Oil-red O (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and reacted with mouse anti-rabbit MMP-3 monoclonal
antibody (Oncogene, USA), mouse anti-rabbit RAM-11 mono-
clonal antibody (Dako, USA), mouse anti-rabbit a-smooth-muscle-
cell (SMC) actin monoclonal antibody (Sigma Chemical, USA),
MMP-1, MMP-2 (Abcam, Cambridge, MA, USA), MMP-3,
MMP-9 (Chemicon, Boston, MA, USA), MMP-12, P-selectin and
MCP-1 polyclonal antibody (Santa Cruz Biotechnology). Sections
reacted with non-immune IgG, secondary antibody only and no
primary and secondary antibodies were used as negative controls.
Histopathological slides were analyzed by use of a computer-
assisted morphometric analysis system (Image-Pro Plus 5.0, Media
Cybernetics, Cambridge, MA, USA). The fibrous cap thickness
and IMT of the aortic plaque were measured at 10 equidistant
points around the cap in each slice; three slices per segment were
measured and the values were averaged. Then, the ratio of the
fibrous cap thickness to IMT was calculated. The positive staining
area of a-actin (SMCs), sirius red (collagens), Oil-red O (lipids) and
RAM-11 (macrophages) was expressed as a percentage of stained
Figure 1. Biochemical measurements in three groups of rabbits. Panel A, B, C and D show the serum levels of TC, LDL-C, TG and HDL-C,
respectively, in three groups of rabbits at week 8 and week 20. Panel E, F, G H, I and J depict the serum levels of hs-CRP, MCP-1, IL-8, IL-18, MMP-1 and
P-selectin, respectively, in three groups of rabbits at week 20. Group D: doxycycline-treated group; Group S: simvastatin-treated group; Control:
control group. *P,0.05 vs. Control group;
#P,0.05 vs. Group S.
doi:10.1371/journal.pone.0039695.g001
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dimensional ultrasonographic and intravascular ultrasound (IVUS) images and blood flow velocities of the abdominal aorta in three groups of rabbits.
Panel B, C, D, E, F and G depict the measurements of IMT, Dd, Vp, Vm, VTI and AIIc in three groups of rabbits before pharmacological triggering. Panel
H, I and J show the measurements of EEMA, PA and PB% in three groups of rabbits before pharmacological triggering. Group D: doxycycline-treated
group; Group S: simvastatin-treated group; Control: control group.*P,0.05 vs. Control group.
doi:10.1371/journal.pone.0039695.g002
Figure 3. Immunohistochemical staining of plaque components in three groups of rabbits. Panel A and B depict the H&E staining of the
abdominal aortic cross-section in a rabbit of the control group, showing an intraluminal thrombus attached to a disrupted plaque (Bars=100 mm).
Panel C show dense a-actin of smooth muscle cells in the doxycycline-treated group (Group D) and simvastatin-treated group (Group S) and sparse a-
actin of smooth muscle cells in the Control group. Sirius-red staining illustrates abundant collagen in Group D and Group S and less collagen in the
Control group. RAM 11 staining demonstrates few macrophages in Group D and Group S and ample macrophages in the Control group. Oil-red O
staining shows a small, moderate and large amount of lipids in Group S, Group D, and Control group, respectively. (Bars=100 mm) Group D:
doxycycline-treated group; Group S: simvastatin-treated group; Control: control group. *P,0.05 vs. Control group; *
#P,0.05 vs. Control group and
P,0.05 vs. Group S.
doi:10.1371/journal.pone.0039695.g003
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high-power fields (6400). The vulnerability index (VI) was derived
as: VI=(macrophages stained %+lipids stained %)/(smooth
muscle cells stained %+collagen stained %) [12]. Plaque rupture
was defined as discontinuity of the fibrous cap with luminal
thrombosis or a buried fibrous cap within a plaque [13].
Gelatin zymography
MMP-2 and MMP-9 enzymatic activities were measured by
gelatin-zymography. The proteins were extracted from snap-
frozen tissue samples of the abdominal aorta and mixted with the
same volume of Tris-Glycine SDS Sample Buffer. The protein
samples were separated by electrophoresis on a sodium dodecyl-
sulfate–10% polyarylamide gels containing 1 mg/ml gelatin
(Sigma, St. Louis, MO, USA) and the gels were rinsed twice in
50 mls of 2.5%(v/v) Triton-X-100 for 30 minutes at room
temperature. Then gels were incubated in fresh incubation-
solution and moderately agitated for 48 hours at 37uC. The gels
were subsequently stained with 2.5% Coomasie brilliant blue R-
250 (Sigma) for 2 hours at room temperature. After destaining for
about 1.5 hours, the enzymatic activities of the MMP-2 and
MMP-9 were displayed as white bands against blue background
and calculated by densitometric analysis.
RT-PCR
Total RNA was extracted from frozen tissue samples of
abdominal aortas, and mRNA expression level of MCP-1,
MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and P-selectin in
the aortic plaque was quantitated by RT-PCR using LightCycler
(Roche Applied Science, Indianapolis, IN, USA) following the
manufacturer’s instruction. The mRNA sequences were obtained
from GenBank (Bethesda, Maryland, USA, Table 1). The
Figure 4. Immunohistochemical staining of the inflammatory markers in the aortic plaque in three groups of rabbits. The left panel
shows protein expression of MCP-1, P-selectin, MMP-1, MMP-2, MMP-3, MMP-9 and MMP-12. The right panel indicates the quantitative analysis of the
results in the left panel. Bars=50 mm. Group D: doxycycline-treated group; Group S: simvastatin-treated group; Control: control group. *P,0.05 vs.
Control group; ** P,0.01 vs. Control group.
doi:10.1371/journal.pone.0039695.g004
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(GAPDH) was taken as an internal RNA control. Quantitative
values were obtained from the threshold cycle value (Ct), the point
with a significant increase in fluorescence [14]. Experiments were
performed in triplicate for each data point.
Cell Experiment
RAW 264.7 macrophage cell line was used to explore the
mechanism of doxycycline induced changes of MMPs and
collagen expression. The RAW 264.7 macrophages were seeded
in the 6-well plate at 60%–70% confluence, pre-incubated with
ox-LDL (100 mg/ml) for 24 hours [15], and divided into
doxycycline-treated group (5 mg/ml) [16] and simvastatin-treated
group (10 mg/ml) [17] and control group without treatment.
Twenty-four hours after treatment, the macrophages were
collected for further analysis. For the assessment of mRNA
expression, the total RNA was extracted and the mRNA
expression levels of MMP-2, MMP-9 and collagen I were
quantitated by RT-PCR. To compare the extent of MMPs
expression in macrophages, cells were coincubated with MMP-2
and rat anti-mouse monoclonal monocyte/macrophage antibody
(MOMA-2, AbD Serotec, Oxford, UK) or with MMP-9 and
MOMA-2. The positively stained cells by immunofluorescence
were displayed with a confocal microscope (Zeiss-710, Zeiss,
Germany) [18]. For quantitative analysis of protein expression
levels of MMP2 and MMP9, western blot was performed as
described previously [18].
Statistical analysis
All statistical analyses involved use of SPSS, v11.0 (SPSS Inc,
Chicago, IL, USA). Quantitative variables are expressed as means
6 SD. Variables with skewed distribution were log-transformed
before the t test. For continuous variables, differences between two
groups were assessed by unpaired Student’s t test, and comparison
of multiple groups involved the use of ANOVA. Categorical data
were analyzed with Kruskal-Wallis and chi-squared tests. A two-
tailed P,0.05 was considered statistically significant.
Results
Administration of doxycycline was tolerated well by all rabbits,
with no adverse effects being observed. Only one rabbit in the
control group died of diarrhea at week 12.
Plasma concentration of doxycycline
The doxycycline plasma levels measured in rabbits corresponded
well with those found in the literature. The plasma concentration of
doxycycline in rabbits at day 1 after treatment was 1.2860.34 mg/
ml, which was an effective plasma drug concentration, and no
significant differences were detected among plasma concentrations
at day 1, week 1, week 4, week 8 and week 12 after doxycycline
administration (2.1160.43,2.0660.35,2.1660.39,2.1160.43and
2.3260.36 mg/ml, respectively, P.0.05).
Serum lipid profile and inflammatory markers
To determine whether doxycycline administration has an effect
on lipid metabolism, serum cholesterol and lipoprotein cholesterol
concentrations were measured. At the beginning of the experi-
ment, serum lipid levels did not differ among the 3 groups of
rabbits (Fig. 1 A, B, C, D). At week 20, simvastatin-treated group
showed a significant reduction in serum TC and LDL-C levels as
compared with the doxycycline-treated group and the control
group (both P,0.05), with no significant difference in serum levels
of TC, TG, HDL-C and LDL-C between doxycycline-treated and
control groups (Fig. 1 A, B, C, D). The serum levels of MCP-1, hs-
CRP, IL-8, IL-18, MMP-1 and P-selectin were substantially lower
in the two treatment groups than in the control group, with no
significant difference in these cytokines between the two treatment
groups (Fig. 1 E, F, G, H, I, J).
High-frequency ultrasonographic measurements
IMT in the aortic plaque was significantly lower in the two
treatment groups than in the control group (both P,0.05), with no
significant difference between doxycycline-treated and simvasta-
tin-treated groups. In contrast, AIIc% was significantly higher in
the two treatment groups than in the control group (both P,0.05).
The values of Dd, Vp, Vm and VTI did not differ among the three
groups of rabbits (Fig. 2 A, B, C, D, E, F, G).
Intravascular ultrasound measurements
Values of EEMA, PA and PB% in the abdominal aorta in the
two treatment groups were lower than those in the control group
(all P,0.05), with no significant difference between the two
treatment groups (Fig. 2 H, I, J). However, values of LA did not
differ among the three groups of rabbits.
Histopathological and immunohistochemical analysis
Doxycycline-treated (257662 mm) and simvastatin-treated
(248657 mm) groups showed a thicker fibrous cap of the aortic
plaque than the control group (113645 mm, both P,0.05). In
contrast, doxycycline-treated (6806203 mm) and simvastatin-
treated (5976159 mm) groups showed a significantly thinner
IMT of the aortic plaque than the control group (9726254 mm,
both P,0.05). As a result, the ratio of the fibrous cap thickness to
IMT of the aortic plaque was significantly larger in doxycycline-
treated (0.3860.03) and simvastatin-treated (0.4760.05) groups
than in the control group (0.1660.04, both P,0.05). After
pharmacological triggering, none of the rabbits in the doxycycline-
treated and simvastatin-treated groups exhibited abdominal aortic
plaque rupture whereas 5 rabbits in the control group (5/9, 56%)
showed abdominal aortic plaque rupture, with the incidence of
Figure 5. Enzymatic activity of MMP-2 and MMP-9 in the aortic
plaque in three groups of rabbits. Panel A shows a representative
zymogram of MMP-2 and MMP-9. Panel B and C depicts the
quantitative analysis of the results in panel A. Group D: doxycycline-
treated group; Group S: simvastatin-treated group; Control: control
group. *P,0.05 vs. Control group; ** P,0.01 vs. Control group.
doi:10.1371/journal.pone.0039695.g005
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the two treatment groups (both P,0.05, Fig. 3A, B).
In comparison with the control group, doxycycline-treated and
simvastatin-treated groups showed increased positive staining area
of a-actin (both P,0.05) and sirius red (both P,0.05) in the
abdominal aorta (Fig. 3C). In contrast, doxycycline-treated and
simvastatin-treated groups showed decreased positive staining area
of RAM-11 (both P,0.05) and Oil-red O (both P,0.05) in the
abdominal aortic segments in comparison with the control group,
despite the fact that positive staining area of Oil-red O was less in
the simvastatin-treated group than in the doxycycline-treated
group (P,0.05) (Fig. 3C). As a result, the plaque vulnerability
index in doxycycline-treated (0.7260.08%) and simvastatin-
treated (0.5860.09%) groups was significantly lower than that in
the control group (3.7960.32%, both P,0.05). The percentage of
cells positively stained for MCP-1, MMP-1, MMP-2, MMP-3,
MMP-9, MMP-12 and P-selectin in the abdominal aortic sections
was remarkably lower in doxycycline-treated and simvastatin-
treated groups than that in the control group (all P,0.05), with no
significant difference between the two treatment groups (Fig. 4).
Enzymatic activities of MMP-2 and MMP-9
The enzymatic activities of MMP-2 and MMP-9 in the aortic
plaque were remarkably reduced in the doxycycline-treated and
simvastatin-treated (P,0.01,0.05) groups compared to the
control group, with no significant difference between the two
treatment groups (Fig. 5 A, B, C).
RT-PCR
The mRNA expression of MCP-1, MMP-1, MMP-2, MMP-3,
MMP-9, MMP-12 and P-selectin in the aortic plaques was
remarkably lower in the doxycycline-treated and simvastatin-
treated groups than in the control group (all P,0.05), with no
significant difference between the two treatment groups (Fig. S1).
Similarly, the mRNA expression of MMP2 and MMP9 in
macrophages was markedly lower in the doxycycline-treated and
simvastatin-treated groups than the control group (P,0.01,0.05),
with no significant difference between the two treatment groups
(Fig. S2A, B). The mRNA expression of collagen I in macrophages
was significantly higher in the doxycycline-treated and simvasta-
tin-treated groups than the control group (P,0.001), with no
significant difference between the two treatment groups (Fig. S2C).
Figure 6. Immunofluorescence and western blot analysis of MMP-2 and MMP-9 expression in vitro. Panel A shows the
immunofluorescence images of MMP-2 in macrophages receiving doxycycline, simvastatin or no treatment. Panel B shows the immunofluorescence
images of MMP-9 in macrophages receiving doxycycline, simvastatin or no treatment. Panel C shows western blot analysis of MMP-2 and MMP-9
expression. Panel D and E are the quantitative analysis of Panel C. Blue color represents DAPI staining, green color MOMA-2 staining and red color
MMP-2 or MMP-9 staining. Bars=20 mm. Group D: doxycycline-treated group; Group S: simvastatin-treated group; Control: control group. **P,0.01,
vs. Control group.
doi:10.1371/journal.pone.0039695.g006
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MMP-2 and MMP-9 were profoundly stained by immunofluor-
escence in macrophages receiving no treatment as compared with
those treated by doxycycline and simvastatin (Fig. 6A, B). The
protein expression levels of MMP-2 and MMP-9 measured by
western blot were markedly lower in the doxycycline-treated and
simvastatin-treated groups than the control group (P,0.01,0.05),
with no significant difference between the two treatment groups
(Fig. 6C, D, E).
Discussion
The most important finding of the present study was that in a
rabbit model of vulnerable aortic plaque, oral administration of
doxycycline markedly inhibited MMPs expression and activities,
local and systemic inflammation, as well as aortic plaque
vulnerability, which was independent of serum lipid levels. These
effects led to a successful prevention of plaque disruption, similar
to the effects of a large dose of simvastatin [10]. To the best of our
knowledge, our study is the first to report the salutary effects of
doxycycline in an animal model of vulnerable plaque.
A major obstacle in evaluating the plaque-stabilizing effects of
interventions is the lack of ideal animal model of vulnerable
plaque. Pathological studies have identified certain characteristics
of human atherosclerotic plaques associated with plaque instability
and rupture: increased necrotic core size and macrophage
infiltration, and decreased smooth muscle cells and collagen
content. These pathological features were observed in the
abdominal aortic plaques of rabbits receiving endothelial injury,
high-fat feeding and pharmacological triggering as in the present
study. Furthermore, the abdominal aorta in rabbits offers an
optimal site for balloon endothelial injury and ultrasound imaging.
Thus, our animal model provides a useful tool for assessing the
therapeutic effects of doxycycline on plaque stability.
Plaque disruption is associated with increased inflammation and
destruction of the extracellular matrix within the plaque, and the
fibrous cap overlying a necrotic core undergoes catastrophic
mechanical breakdown. The finding that mRNA, protein and
activity levels of MMPs were increased in vulnerable plaques,
particularly at the shoulder of the fibrous cap, has led to the notion
that a broad-spectrum and/or high activity of MMPs, especially
associated with inflammation, may contribute to pathological
plaque matrix destruction, including fibrillar collagens [3,4]. By
this mechanism, MMPs may promote plaque destabilization and
disruption, the main cause of acute coronary syndromes in human.
Thus, MMPs represent a potential therapeutic target for plaque
stabilization.
Recent studies have demonstrated that doxycycline, a tetra-
cycline derivative, is a non-specific broad-spectrum and potent
inhibitor of MMPs. Using chemically modified tetracyclines, it has
been confirmed that the antibiotic and anti-MMPs activities lie in
different regions of the molecule. This family of antibiotics can
inhibit the activity of secreted MMPs because they bind the
calcium and zinc necessary for maintenance of proper conforma-
tion of the MMPs [19,20]. A number of studies have been
performed to examine the effects of doxycycline in atherosclerosis
but the results are controversial. Manning MW et al. found that
doxycycline had no effect on the extent of atherosclerosis in saline-
or AngII-infused mice. In contrast, doxycycline markedly reduced
the incidence and severity of abdominal aortic aneurysm [7].
Recently, Sheth RA et al showed that doxycycline dose-
dependently inhibited MMPs activities measured by optical
molecular imaging in a mouse model of abdominal aortic
aneurysm [21]. Ohshima S, et al presented evidence of SPECT
molecular imaging that minocycline, another tetracycline deriva-
tive, reduced plaque inflammation and stabilized atherosclerotic
plaques in rabbits [22]. The MIDAS pilot trial revealed that in
patients with acute coronary syndromes, doxycycline treatment
significantly reduced the plasma levels of high-sensitivity C-
reactive protein [6]. Another clinical trial reported that in patients
undergoing carotid endarterectomy, doxycycline treatment sig-
nificantly reduced the concentration of MMP-1 in carotid plaques
due to decreased MMP-1 transcript, but the local concentrations
of MMP-2, MMP-3, or MMP-9 were not altered [5]. On the other
hand, administration of an oral active MMP-3 inhibitor (CGS
27023A) failed to exert any beneficial effect on atherosclerotic
lesions measured in the aortas of LDL receptor knockout mice
[23].
In the present study, we found that oral administration of
doxycycline for 12 weeks in a rabbit model of vulnerable plaque
resulted in a substantial inhibition of MMPs expression, reduction
of local and systemic inflammation and enhancement of aortic
plaque stability. Several lines of evidence were presented to
support our conclusion. First, abdominal ultrasonography and
intravascular ultrasound revealed decreased plaque burden,
reduced positive vascular remodeling, and increased plaque
density in the doxycycline-treated group as compared with the
control group. Second, immunohistochemical and molecular
biological studies showed a significant decrease in the mRNA
and protein expression levels of MCP-1, MMP-1, MMP-2, MMP-
3, MMP-9, MMP-12 and P-selectin in the aortic plaques, and a
substantial decline in the serum levels of MCP-1, hs-CRP, IL-8,
IL-18, MMP-1 and P-selectin after doxycycline treatment. Third,
histopathological studies demonstrated a dramatic increase in the
fibrous cap thickness and a reduction in IMT and plaque
vulnerability index. Finally, no rabbits in the doxycyclin-treated
group showed evidence of plaque disruption, indicating a
successful prevention of plaque rupture in these rabbits. A notable
finding in this study was that different from simvastatin,
doxycycline had no effect on serum lipid levels and reduced only
moderately the plaque lipid content. Nonetheless, doxycycline
therapy markedly inhibited MMPs expression and local inflam-
mation, leading to stable plaque phenotype. The major mechan-
isms underlying these salutary effects of doxycycline may involve
downregualted expression of MMP2 and MMP9 and upregulated
expression of collagen I in macrophages. These results lend strong
support to the notion that doxycycline treatment is of potent
plaque-stabilizing effect which is independent of serum lipid levels,
a finding consistent with our previous anti-inflammatory studies
[24].
Statins have been recognized as the most potent drugs for
stabilizing atherosclerotic plaques mainly through lipid-lowering
and anti-inflammation effects. In addition, statins has a strong
effect on reducing MMPs protein expression and activities in
animal models of atherosclerosis [22]. Thus, we made a head-to-
head comparison between simvastatin and doxycycline for their
therapeutic effects on vulnerable atherosclerotic plaques, and a
high dose (5 mg/kg/d) of simvastatin was used as a comparison
standard. There was a great variation in the dosing of doxycycline
for rabbits in the literature and we chose the commonly used
antimicrobial dose (10 mg/kg/d) of doxycycline for rabbits [8].
We found that apart from the serum levels of TC, LDL-C and
TG, which were significantly higher in the doxycycline-treated
group than the simvastatin-treated group, all serological, ultra-
sonographic, pathologic, immunohistochemical and mRNA ex-
pression measurements showed no significant difference between
the two treatment groups. These results suggested that despite of
the lack of lipid-lowering effect, doxycycline was as potent as
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tion, and enhancing plaque stability. In view of the low incidence
of side effects of doxycycline, especially at a subantimicrobial dose,
this drug may provide a novel approach to the stabilization of
vulnerable plaques. Besides, since the mechanisms of doxycycline
and simvastatin treatment may involve different signaling path-
ways, combinatorial administration of the two drugs might offer a
synergistic effect on the prevention of plaque disruption.
Several limitations of this study should be mentioned. First, the
sample size in the present study was small and our primary
conclusion needs confirmation by further studies with a large
sample size. Second, although we made careful efforts in choosing
the optimal dose of doxycycline, the dose-effect and time-effect of
doxycycline therapy was not examined. Third, the detailed
molecular mechanisms by which doxycycline inhibited MMPs
expression and activity and attenuating plaque inflammation were
not explored and further in vitro studies were required to dissect
possible signaling pathways involving in this novel therapy. Finally,
plaque rupture in our animal model may not totally simulate that
in patients with acute coronary syndrome and the plaque-
stabilizing effect of doxycycline needs to be tested in clinical trial.
In conclusion, doxycycline at a common antimicrobial dose
substantially inhibited MMPs expression, local inflammation and
plaque vulnerability, leading to significant reduction of plaque
disruption in a rabbit model of vulnerable plaque. These effects
were similar to a large dose of simvastatin and independent of
serum lipid levels. The major mechanism underlying these effects
involves downregualted expression of MMP2 and MMP9 and
upregulated expression of collagen I in macrophages. Thus,
doxycycline administration may provide a novel approach for the
treatment of vulnerable atherosclerotic plaques.
Supporting Information
Figure S1 Relative mRNA expression of the inflamma-
tory markers in the aortic plaque in three groups of
rabbits. Panel A, B, C, D, E, F, G and H depict the relative
mRNA expression of the inflammatory markers in the aortic
plaque in three groups of rabbits. Group D: doxycycline-treated
group; Group S: simvastatin-treated group; Control: control
group. *P,0.05, vs. Control group.
(TIF)
Figure S2 Relative mRNA expression of the inflamma-
tory markers in macrophages receiving different treat-
ments. Panel A, B and C depict the relative mRNA expression of
MMP-2, MMP-9 and Collagen I in macrophages receiving
doxycycline, simvastatin or no treatment. Group D: doxycycline-
treated group; Group S: simvastatin-treated group; Control:
control group. *P,0.05, vs. Control group. **P,0.01, vs. Control
group. ***P,0.001, vs. Control group.
(TIF)
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